National Biologics Manufacturing Centre Launched
News Oct 05, 2015
The new Centre was opened by Jo Johnson, Minister of State for Universities and Science and Steve Bagshaw, CEO of Fujifilm Diosynth Biotechnologies. The new Centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.
Biopharmaceuticals are medicines produced through biotechnology which represent the cutting-edge of biomedical research. They are delivering significant advances in healthcare with completely new medicines being developed for serious illnesses, including cancer, blood conditions, auto-immune disorders such as rheumatoid arthritis, and neurological disorders like multiple sclerosis. The use of biotechnology can also facilitate the development of the next generation of personalised medicines for specific diseases and patient groups.
The National Biologics Manufacturing Centre was announced in 2012 as part of the UK strategy for Life science. The Strategy outlined a vision for the UK to be a global leader in the life science sector. The £38m investment was made by the Department for Business Innovation and Skills through Innovate UK.
Launching the new Centre, Jo Johnson MP, Minister of State for Universities and Science said, “We want the UK to be the best place in Europe to innovate which is why we have invested in this new Centre to capitalise on the North East’s expertise in medicines manufacturing and strengthen the UK’s position as a global leader in life sciences. As part of our successful Catapult network, the Centre will bridge the gap between business and academia and help to turn great ideas into commercial reality.”
Steve Bagshaw, CEO of FUJIFILM Diosynth Biotechnologies said, “The National Biologics Manufacturing Centre will provide a valuable resource for the biologics sector in the UK. The Centre will help the UK capture more of the expanding global market in high value, high quality manufacture of biologic medicines and make an important contribution to equipping the UK workforce to meet the challenges faced in this sector”.
Nigel Perry, CEO of CPI said, “The launch of the National Biologics Manufacturing Centre will significantly increase the UK’s manufacturing capability in biologics and strengthen the UK’s position as the location of choice for life science companies. This open access facility will enable companies to test and trial new ideas cheaply and quickly with minimised risk, allowing new innovative medicines to reach the market faster and provide improved care for patients and better opportunities for businesses”.
Chris Dowle, Director of Biologics at CPI added “CPI is supporting the commercialisation of research by promoting collaboration with industry across the supply chain, from research through to manufacture and clinic. Utilising the new Centre we will help companies to commercialise ideas and take them to market faster and with less risk. We are already underway with a number of projects which are helping UK companies prove their technologies in an industrially relevant environment”.
Ruth McKernan, Chief Executive of Innovate UK, said: “This new biologics manufacturing facility will be an important addition to CPI’s world-class capabilities in high value manufacturing. It will also work closely with our ground-breaking three healthcare Catapults and keep the UK at the forefront of a sector we have long excelled in.”
CPI is the process industry element of the UK government’s High Value Manufacturing Catapult – the network of technology and innovation centres tasked with stimulating growth within key manufacturing sectors throughout the UK. CPI works with industry, academia and the public sector to develop, prove, prototype and scale up the next generation of products and processes.
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018
2nd International Conference on Food Science and Bioprocess Technology
Oct 01 - Oct 03, 2018